TWA
VIR icon

TCI Wealth Advisors’s Vir Biotechnology VIR Stock Holding History

TCI Wealth Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-149
Closed -$3.47K – 2167
2023
Q1 		$3.47K Sell
149
-92
-38% -$2.35K ﹤0.01% 1769
2022
Q4 		$6.1K Sell
241
-122
-34% -$2.99K ﹤0.01% 1395
2022
Q3 		$7K Buy
363
+133
+58% +$3.38K ﹤0.01% 1300
2022
Q2 		$6K Hold
230
– – ﹤0.01% 1420
2022
Q1 		$6K Buy
230
+105
+84% +$3.11K ﹤0.01% 1473
2021
Q4 		$5K Buy
125
+5
+4% +$196 ﹤0.01% 1730
2021
Q3 		$5K Buy
120
+57
+90% +$2.47K ﹤0.01% 1664
2021
Q2 		$3K Buy
63
+4
+7% +$182 ﹤0.01% 1865
2021
Q1 		$3K Buy
+59
New +$3.18K ﹤0.01% 1602

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

TCI Wealth Advisors's VIR Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Vir Biotechnology (VIR) in Q2 2023, closing a stake of 149 shares — an estimated $3.47K sold.

TCI Wealth Advisors first reported a position in VIR in Q1 2021 and held it in 9 quarters. The position peaked at $7K in Q3 2022. 226 funds tracked by Wall St. Rank hold VIR as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Vir Biotechnology position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 149 Vir Biotechnology shares in Q2 2023, an estimated $3.47K.
  • TCI Wealth Advisors first reported a position in Vir Biotechnology in Q1 2021 and held it in 9 quarters.
  • TCI Wealth Advisors's Vir Biotechnology position peaked at $7K in Q3 2022.
  • 226 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.